O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1. by Phoomak, Chatchai et al.
UC Davis
UC Davis Previously Published Works
Title
O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and 
MAN1A1.
Permalink
https://escholarship.org/uc/item/5q904034
Journal
Oncogene, 37(42)
ISSN
0950-9232
Authors
Phoomak, Chatchai
Silsirivanit, Atit
Park, Dayoung
et al.
Publication Date
2018-10-01
DOI
10.1038/s41388-018-0366-1
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Oncogene (2018) 37:5648–5665
https://doi.org/10.1038/s41388-018-0366-1
ARTICLE
O-GlcNAcylation mediates metastasis of cholangiocarcinoma
through FOXO3 and MAN1A1
Chatchai Phoomak1,2 ● Atit Silsirivanit1,2 ● Dayoung Park3,4 ● Kanlayanee Sawanyawisuth1,2 ●
Kulthida Vaeteewoottacharn1,2 ● Chaisiri Wongkham1,2 ● Eric W.-F. Lam 5 ● Chawalit Pairojkul2,6 ●
Carlito B. Lebrilla 3 ● Sopit Wongkham1,2
Received: 17 August 2017 / Revised: 23 May 2018 / Accepted: 25 May 2018 / Published online: 18 June 2018
© The Author(s) 2018. This article is published with open access
Abstract
The leading cause of death in cancer patients is metastasis, for which an effective treatment is still necessary. During
metastasis, cancer cells aberrantly express several glycans that are correlated with poor patient outcome. This study was
aimed toward exploring the effects of O-GlcNAcylation on membranous N-glycans that are associated with the progression
of cholangiocarcinoma (CCA). Global O-GlcNAcylation in CCA cells was depleted using specific siRNA against O-
GlcNAc transferase (OGT), which transfers GlcNAc to the acceptor proteins. Using an HPLC-Chip/Time-of-Flight (Chip/
TOF) MS system, the N-glycans associated with O-GlcNAcylation were identified by comparing the membranous N-glycans
of siOGT-treated cells with those of scramble siRNA-treated cells. In parallel, the membranous N-glycans of the parental
cells (KKU-213 and KKU-214) were compared with those of the highly metastatic cells (KKU-213L5 and KKU-214L5).
Together, these data revealed that high mannose (Hex9HexNAc2) and biantennary complex (Hex5HexNAc4Fuc1NeuAc1) N-
linked glycans correlated positively with metastasis. We subsequently demonstrate that suppression of O-GlcNAcylation
decreased the expression of these two N-glycans, suggesting that O-GlcNAcylation mediates their levels in CCA. In
addition, the ability of highly metastatic cells to migrate and invade was reduced by the presence of Pisum Sativum
Agglutinin (PSA), a mannose-specific lectin, further indicating the association of high mannose type N-glycans with CCA
metastasis. The molecular mechanism of O-GlcNAc-mediated progression of CCA was shown to proceed via a series of
signaling events, involving the activation of Akt/Erk (i), an increase in FOXO3 phosphorylation (ii), which results in the
reduction of MAN1A1 expression (iii) and thus the accumulation of Hex9HexNAc2 N-glycans (iv). This study demonstrates
for the first time the association between O-GlcNAcylation, high mannose type N-glycans, and the progression of CCA
metastasis, suggesting a novel therapeutic target for treatment of metastatic CCA.
Introduction
Metastasis, a progressive process in which cancer cells
develop the ability to colonize distant organs, is responsible
for the majority of cancer deaths [1]. The occurrence of
metastasis is particularly high for cholangiocarcinoma
* Carlito B. Lebrilla
cblebrilla@ucdavis.edu
* Sopit Wongkham
sopit@kku.ac.th
1 Department of Biochemistry, Faculty of Medicine, Khon Kaen
University, Khon Kaen 40002, Thailand
2 Cholangiocarcinoma Research Institute, Khon Kaen University,
Khon Kaen 40002, Thailand
3 Department of Chemistry, University of California, Davis, CA
95616, USA
4 Department of Surgery, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA 02115, USA
5 Department of Surgery and Cancer, Imperial Centre for
Translational and Experimental Medicine, Imperial College
London, London W12 0NN, UK
6 Department of Pathology, Faculty of Medicine, Khon Kaen
University, Khon Kaen 40002, Thailand
Electronic supplementary material The online version of this article
(https://doi.org/10.1038/s41388-018-0366-1) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
(CCA), a cancer of the bile duct. CCA is highly prevalent in
southeast Asia and ranks among diseases with the highest
mortality rates, following HIV and stroke [2–4]. At present,
few effective treatments for advanced CCA outside of sur-
gical resection is available to prolong the survival of the
patients.
Modification of proteins via glycosylation is one of the
most common post-translational processes that exercises
key roles in homeostatic functions, e.g., inflammation,
cell–cell interactions, morphogenesis, and immunity.
Aberrant glycosylation is commonly found in cancer, some
of which associate with metastatic processes [5–7]. The
correlation between the membranous glycosylation and the
progression of cancer has been collectively reported [8–11].
In CCA, several aberrant glycans and glycoproteins are
correlated with CCA progression, such as carbohydrate
antigen 19-9, carcinoembryonic antigen, mucin (MUC)1,
MUC2, MUC5AC, serum α1β-glycoprotein, and several
lectin-binding glycans [12–17].
O-GlcNAcylation is a form of protein modification,
where a single moiety of N-acetylglucosamine (GlcNAc) is
added to the target protein without further elongation or
modification into more complex structures [18–20]. Mod-
ification with O-GlcNAc is a reversible process, in which
GlcNAc is added to or removed from the amino acid Ser/
Thr of a protein by O-GlcNAc transferase (OGT), or O-
GlcNAcase (OGA), respectively [19]. Alterations of O-
GlcNAcylation can dysregulate protein function, disrupting
processes such as protein phosphorylation, stability,
protein–protein interaction, and protein localization [21].
Accordingly, aberrant O-GlcNAcylation relates to a number
of diseases, including cancer [22]. In particular, the increase
of O-GlcNAcylation in tumor tissues has been shown to
occur with the progression of cancers, including cancers of
the breast, colon, liver, lung, pancreas and prostate [23] as
well as CCA [24]. In contrast, suppression of OGT in CCA
cells could decrease invasion and migratory capabilities
[25]. Moreover, we have previously shown that CCA cells
with high metastatic abilities have higher O-GlcNAcylation
levels than those with low metastasis [26]. Nevertheless,
how O-GlcNAcylation modulates progression of CCA
metastasis remains unclear.
To our knowledge this study reports for the first time the
molecular link between O-GlcNAcylation and membranous
high mannose type N-glycans related to cancer progression.
Comparing the glycomic data from siOGT treated and
control cells with those from high and low metastatic cells,
the metastatic-specific membranous N-glycans that were
regulated by O-GlcNAcylation were identified. Subse-
quently, the molecular mechanism of how O-
GlcNAcylation regulates the metastasis-related N-glycans
were elucidated. These membranous N-glycans could be
new prognostic markers or novel therapeutic targets for
metastatic CCA.
Results
Expression of specific high mannose type N-glycans
may be modulated by O-GlcNAcylation
We first investigated the involvement of O-GlcNAcylation in
the membranous N-glycan expression. N-Glycan analysis was
performed by graphitized carbon column chip-mounted nano-
LC-MS. The N-glycan profiles of siOGT and control scramble
siRNA (sc) treated cells were determined and compared. LC-
MS analysis yielded nearly 130 N-glycans over a dynamic
range of four orders of magnitude. The majority of membra-
nous N-glycan on CCA cells were high mannose type N-
glycans (Fig. 1a, b and Table S1). A ratio of N-glycan
intensity of siOGT to sc higher than 1.2 was classified as up-
regulated and a ratio lower than 0.8 were set as down-
regulated. There were 16 N-glycans differentially expressed in
KKU-213 and 31 in KKU-214 (Table S1). Among these, only
five N-glycans were commonly altered when O-
GlcNAcylation was suppressed in both KKU-213 and
KKU-214 cells (Fig. 1c). Specifically, Hex9HexNAc2, Hex6-
HexNAc2Fuc1, and Hex5HexNAc4Fuc1NeuAc1 were down-
regulated, whereas Hex3HexNAc5Fuc1 and Hex3HexNAc4-
Fuc1 were up-regulated. The synthesis of these five N-glycans
may be associated with O-GlcNAcylation in CCA cells.
Expressions of specific high mannose type N-glycans
associate with metastatic ability of CCA cells
We next sought to identify the membranous N-glycans that
may be correlated with metastasis. The expression profiles of
the membranous N-glycans from two pairs of CCA cell lines
with different metastatic potentials, the parental (KKU-213
and KKU-214) and the highly metastatic (KKU-213L5 and
KKU-214L5) cells, were determined. A total of 136 N-
glycans were found in both parental and highly metastatic
CCA cells with different expression levels (Fig. 2a, b and
Supplementary Table S2). There were 20 N-glycans differ-
entially expressed between KKU-213 and KKU-213L5, and
30 N-glycans between KKU-214 and KKU-214L5 (Supple-
mentary Table S2). Of these, eight differentially expressed N-
glycans in both KKU-213L5 and KKU-214L5 were revealed.
Six N-glycans were up-regulated (Hex5HexNAc4Fuc2-
NeuAc2, Hex8HexNAc2, Hex9HexNAc2, Hex5HexNAc3Fuc1,
Hex5HexNAc4Fuc1NeuAc1, and Hex7HexNAc2) while two
were down-regulated (Hex5HexNAc4Fuc2NeuAc1 and Hex7-
HexNAc6NeuAc1) (Fig. 2c). These eight N-glycans may
associate with the metastatic abilities of CCA cells.
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Fig. 1 Suppression of O-GlcNAcylation altered N-glycans expression in CCA cells. a Quantitative analysis of membranous N-glycans were
determined using the Agilent MassHunter Qualitative analysis software. The colors of each peak represent the type of N-glycans; red for high
mannose (HM) glycans; orange for undecorated complex/hybrid (C/H) glycans; green for fucosylated complex/hybrid (C/H−F) glycans; blue for
sialylated complex/hybrid (C/H−S) glycans; and purple for fucosylated-sialylated complex/hybrid (C/H-FS) glycans. b Heat map represented
numbers of differentially expressed N-glycans between scramble and siOGT-treated CCA cells (KKU-213 and KKU-214). Triplicate samples were
analyzed. c The five N-glycans that were differentially expressed in both cell lines when O-GlcNAcylation was suppressed using siOGT
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Fig. 2 N-glycan profiles of parental and highly metastatic CCA cells. The membranous N-glycans of parental (KKU-213 and KKU-214) and
highly metastatic cells (KKU-213L5 and KKU-214L5) were compared. a Chromatograms of N-glycans released from CCA cells. The colors of
each peak represent the type of N-glycans: red, high mannose (HM) glycans; orange, undecorated complex/hybrid (C/H) glycans; green,
fucosylated complex/hybrid (C/H−F) glycans; blue, sialylated complex/hybrid (C/H−S) glycans; purple, fucosylated-sialylated complex/hybrid
(C/H-FS) glycans. b Heat map represents the numbers of differentially expressed N-glycans between parental and highly metastatic CCA cells.
Triplicate samples were analyzed. c Given the expression of parental cells (KKU-213 and KKU-214) as 1, eight N-glycans were differentially
expressed in both highly metastatic CCA cells
O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1 5651
Two membranous N-glycans are associated with
metastatic activities and O-GlcNAcylation
To determine the N-glycans that may be involved in
metastasis under the modulation of O-GlcNAcylation, the
membranous N-glycans associated with O-GlcNAcylation
(Fig. 1c) and those associated with metastatic potential (Fig.
2c) were aligned. As shown in Fig. 3a, Hex9HexNAc2 and
Hex5HexNAc4Fuc1NeuAc1, two N-glycans were commonly
found in both data sets. To confirm the structures of the
predicted N-glycans, the structures of Hex9HexNAc2 and
Hex5HexNAc4Fuc1NeuAc1 were analyzed using graphi-
tized carbon column chip-mounted nano-LC-MS/MS. The
predicted N-glycans were confirmed by MS/MS, as pre-
cursor m/z 942.33 for Hex9HexNAc2, a high mannose type
N-glycan (Fig. 3b, upper panel) and precursor m/z 693.59
for Hex5HexNAc4Fuc1NeuAc1, a biantennary complex type
N-glycan (Fig. 3b, lower panel).
Suppression of O-GlcNAcylation reduces expression
of membranous high mannose type N-glycans
The high mannose type N-glycan, Hex9HexNAc2, was the
highest abundant in CCA cells (Figs 1a and 2a) and
therefore was selected for further study. To confirm the
connection between the expression of the high mannose
type N-glycans at the cell surface and intracellular O-
GlcNAcylation, the expression of high mannose type N-
glycans in the siOGT-treated vs. scramble siRNA-treated
cells were determined. Both Pisum Sativum Agglutinin
(PSA) and Concanavalin A (Con A) have been used to
detect high mannose type N-glycan in several studies [27–
30]. Our preliminary study using lectin-histochemistry of
PSA and Con A in tumor tissues from CCA patients
revealed that PSA but not Con A could differentiate non-
metastatic from. metastatic CCA tissues (Supplementary
Figure S1). The PSA signal was strongly positive in CCA
tissues with metastasis, weaker in non-metastatic tissue, and
negative with hepatocytes. Con A, in contrast, reacted
strongly with both metastatic and non-metastatic CCA, as
well as hepatocytes. On the basis of these observations, we
selected to use PSA to detect high mannose type N-glycans
in the subsequent study.
High mannose type N-glycans expressed at the cell
surface were quantified using cytofluorescent staining of
PSA, a mannose binding lectin. The specificity of PSA to
mannosylate N-glycan was first determined using a sugar
inhibition test. As shown in Fig. 3c, the PSA-
cytofluorescent staining was localized at cell mem-
branes. Adding 0.3 M D-mannose to neutralize the bind-
ing ability of PSA significantly diminish the staining
signal of PSA. PSA-cytofluorescent staining was next
performed and compared between the siOGT-treated cells
and the scramble siRNA-treated cells. The PSA-
cytofluorescent staining signals were reduced in siOGT-
treated cells compared with those of scramble control cells
(Fig. 3d). Similar patterns were observed for both parental
and highly metastatic CCA cells. Quantitative analysis of
the cytofluorescent signals are presented in Fig. 3e. The
PSA-binding signals were significantly decreased in
siOGT-treated cells (P < 0.05) and the reduction was more
pronounced in the highly metastatic cells compared to the
parental cells. These data connect the intracelluar O-
GlcNAcylation to the expression of cell surface high
mannose type N-glycans. In addition, higher basal PSA-
binding signals of the highly metastatic cells compared to
the parental cells were also observed in both cell lines
(Fig. 3d, e) (P < 0.05). This may indicate the involvement
of high mannose type N-glycans in the metastatic phe-
notype of CCA cells.
Cell surface high mannose type N-glycans promote
progression of CCA metastasis
To demonstrate the association of cell surface high mannose
type N-glycans with CCA progression, the surface high
mannose type N-glycans were masked with PSA prior to
metastatic activity assays. To prevent the possible cell
aggregation caused by lectin binding, the appropriate con-
centration of PSA was first optimized. CCA cells were
treated with 0–100 µg/ml of PSA for 1 h and the aggregated
cells were determined under a microscope. No aggregated
cells were observed at PSA 6.25–12.5 µg/ml (Supplemen-
tary Figure S2), therefore, PSA at 5 and 10 µg/ml were used
to neutralize high mannose glycans at the cell surface. As
shown in Fig. 4a, PSA treatment had no effect on growth of
CCA cells either in the presence of 2% or 5% fetal bovine
serum (FBS). The highly metastatic cells exhibited higher
migration capability than the parental cells as shown in the
wound scratch and migration assays (Fig. 4b, c). CCA cells
treated with 10 µg/ml of PSA did decrease the cell migration
abilities of both parental and highly metastatic cells, but to a
lesser extent in the parental cells. In the wound scratch
assay, PSA treatment extended the time of wound closing of
highly metastatic cells from 12 h to more than 24 h (Fig.
4b). Moreover, treated cells with PSA significantly
decreased the migratory abilities of the parental cells to 40%
and those of highly metastatic cells to 20% relatively to the
control cells (P < 0.001) (Fig. 4c). Similar effects were
observed in the invasion assay. PSA treatment markedly
decreased the number of invaded cells by 42–43% for
parental cells (P < 0.05; P < 0.01) and 25–30% for highly
metastatic cells (P < 0.01; P < 0.001) in both cell lines (Fig.
4d). These data highlight the significance of the surface high
mannose type N-glycans in promoting the progression of
CCA metastasis.
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Fig. 3 The expression levels of membranous N-glycans were modulated by O-GlcNAcylation. a Expression of high mannose type N-glycan,
Hex9HexNAc2 and biantennary complex type N-glycan, Hex5HexNAc4Fuc1NeuAc1, were found to be associated with metastatic ability and O-
GlcNAcylation. b The MS/MS spectra confirmed glycan structures of both N-glycans; high mannose type (m/z 942.33) and for biantennary
complex type (m/z 693.59). c PSA-cytofluorescence stained high mannose glycans at the cell membrane. The specificity of PSA to mannosylated
glycan was proved by sugar inhibition test. d PSA-cytofluorescent staining was reduced in siOGT-treated cells. e Histograms and graphs represent
the quantitative levels of PSA-fluorescent signals. The results are mean ± SEM of one representative from two independent experiments; *P <
0.05, student’s t test
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O-GlcNAcylation upregulates high mannose type N-
glycans via decreasing MAN1A1 and FOXO3
expression
The molecular mechanisms by which O-GlcNAcylation
controlled the expression level of high mannose type N-
glycans were further explored. The biosynthesis of all N-
glycans starts in the endoplasmic reticulum (ER), and the
elongation process for the peripheral glycan moieties
occurs in the Golgi apparatus [18, 31]. The core N-glycan
structure is mannosylated in the ER to yield Hex9HexNAc2,
trimmed back by α1,2-mannosidases, e.g., α1,2-mannosi-
dase IA (MAN1A1) in the Golgi apparatus to form
Hex5HexNAc2, and further elongated to hybrid and com-
plex types (Fig. 5a). Therefore, the accumulation of
Hex9HexNAc2 is likely due to the decrease in expression of
MAN1A1. We first tested whether MAN1A1 expression
was modulated via O-GlcNAcylation. The expression of
MAN1A1 was determined in the parental and highly
metastatic CCA cells treated with siOGT. As shown in Fig.
5b, siOGT significantly reduced the level of O-
GlcNAcylation as determined by the levels of O-
GlcNAcylated proteins (OGP). Compared to untreated
cells, siOGT treatment dramatically reduced O-
GlcNAcylation of the parental cells 0.20-fold and of the
highly metastatic cells 0.25 fold. Suppression of O-
Fig. 4 PSA treatment reduced migration and invasion abilities of CCA
cells. Treatment of PSA in the parental cells, KKU-213 and KKU-214,
and highly metastatic CCA cells, KKU-213L5 and KKU-214L5, for
24 h had no effect on (a) cell proliferation, but significantly affected
(b, c) cell migration and (d) invasion. The numbers of migrated and
invaded cells were compared with the non-treated control cells given
as 100%. The results are mean ± SEM of two independent experi-
ments; *P < 0.05, **P < 0.01, ***P < 0.001, student’s t test
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GlcNAcylation indeed increased expression of MAN1A1
in all siOGT-treated cells. In contrast, inhibition of OGA
by PUGNAc, elevated O-GlcNAcylation and decreased
MAN1A1 expression compared with those of control cells
(Fig. 5c). The data supports the link between O-
GlcNAcylation levels and MAN1A1 expression.
As FOXO3, a member of Forkhead box (FOX) tran-
scriptional factors, has been suggested to regulate MAN1A1
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expression (http://www.sabiosciences.com/chipqpcrsearch.
php), we next tested whether FOXO3 expression was also
modulated by O-GlcNAcylation. Similar to MAN1A1, the
expression of FOXO3 increased in all siOGT-treated cells
and decreased in PUGNAc treated cells (Fig. 5b, c). The
data imply that O-GlcNAcylation affects MAN1A1
expression by modulating FOXO3 expression.
To reveal whether O-GlcNAcylation affects CCA
metastasis, the progression of the parental and highly
metastatic CCA cells were compared in siOGT and
scramble siRNA-treated cells. siOGT treatment suppressed
O-GlcNAcylation and reduced the migration and invasion
abilities of both parental and highly metastatic CCA cells
(P < 0.001) (Fig. 5d). To demonstrate whether MAN1A1
affects migration and invasion of CCA cells, MAN1A1
activity was inhibited using kifunensine, a specific inhibitor
of mannosidase 1. As demonstrated in Fig. 5e, the migra-
tion/invasion abilities of kifunensine treated cells were
significantly increased relatively to those of the control
cells. Moreover, the inhibition effect of OGT silencing on
the reduction of migration and invasion could be rescued by
kifunensine treatment ~2 fold compared to siOGT-treated
cells (Fig. 5f). These data support the connection of O-
GlcNAc modifcation and MAN1A1 with the migration and
invasion capabilities of CCA cells.
O-GlcNAcylation regulates MAN1A1 expression via
activating Akt/Erk signaling and modulating
FOXO3 stability
We further elucidated how O-GlcNAcylation regulates
expression of MAN1A1 via FOXO3. The activations of
Akt, Erk, and Ikk, which are modulated by O-GlcNAc
modification and are the major kinases that regulate the
expression of FOXO3 [32], were proposed to be the con-
nection between O-GlcNAcylation and FOXO3. The
phosphorylations of Akt, Erk, and Ikk were hence deter-
mined in the siOGT-treated cells. As shown in Fig. 6a, the
levels of pAkt/Akt and pErk/Erk, but not pIkk/Ikk, were
markedly decreased in the OGT knocked down cells. All
the data at this stage indicated that suppression of O-
GlcNAcylation inhibits the activation of Akt and Erk, which
subsequently upregulates FOXO3 activity and MAN1A1.
We next explored whether activation of Akt and Erk
directly modulates FOXO3 expression. An allosteric inhi-
bitor of Akt, MK-2206, was used to inhibit Akt activity in
the high metastatic CCA cells. In the presence of MK-2206,
phosphorylation of Akt was reduced in a dose dependent
manner. As a result, phosphorylation of FOXO3 at Thr-32
was suppressed, whereas expression of total FOXO3 and
MAN1A1 were dependently increased with increasing
doses of MK-2206 (Fig. 6b). Similar observations were
obtained when PD98059 (2′-amino-3′-methoxyflavone), a
selective MEK inhibitor, was used to inhibit Erk activation.
Phosphorylation of Erk was reduced by PD98059 treatment
in a dose dependent fashion. The treatment also decreased
phosphorylation of FOXO3 at Ser-294 and increased
expression of FOXO3 and MAN1A1 (Fig. 6c). The inac-
tivation of Akt and Erk signaling pathways had no effect on
the status of O-GlcNAcylation in CCA cells (Figure S3).
These results demonstrate the direct effects of Akt and Erk
activation on FOXO3 and MAN1A1 expression.
As Akt phosphorylation of FOXO3 has been shown to
increase the degradation of FOXO3, we next explored
whether Akt affects FOXO3 stability in CCA cells. The
stability of FOXO3 was determined following cyclohex-
imide (CHX) treatment. As shown in Fig. 6d, the stability of
FOXO3 was prolonged by MK-2206 treatment, with a half-
life of ∼5 h for MK-2206 treated cells and ∼1.5 h for the
control cells. Together, Akt/Erk inhibitors inactivated Akt/
Erk phosphorylation, resulting in the reduction of FOXO3
phosphorylation, which in turn increased the stability of
FOXO3 and expression of MAN1A1.
To demonstrate the link between Akt activation and the
function of MAN1A1 on CCA progression, we first
investigated the migration and invasion of CCA cells in the
presence of an Akt inhibitor, MK-2206. As shown in Fig.
6e, MK-2206 treatment markedly decreased the migration
of CCA to 40% and 60% in KKU-213L5 and KKU-214L5,
respectively. Moreover, these effects could be reversed by
inhibiting MAN1A1 activity using kifunensine. Treatment
of cells with MK-2206 and kifunensine significantly
increased the motility 1.4–2 folds higher than those of MK-
2206 treated cells (P < 0.001). Similar results were observed
for their invasion abilities (Fig. 6f). Collectively, our data
show that O-GlcNAcylation promotes progression of CCA
metastasis via activation of Akt, which consequently
represses FOXO3 and MAN1A1 expression.
Fig. 5 O-GlcNAcylation regulated migration and invasion abilities of
CCA cells via FOXO3 and MAN1A1 expression. a N-linked glycan
synthesis pathway in Golgi apparatus. b siOGT effectively suppressed
O-GlcNAcylation in parental (KKU-213 and KKU-214) and highly
metastatic (KKU-213L5 and KKU-214L5) CCA cells as the levels of
O-GlcNAcylated proteins (OGP) were reduced. The siOGT treatment
suppressed expression of MAN1A1 and FOXO3. c PUGNAc treat-
ment could increase OGP and reduce the expression of MAN1A1 and
FOXO3 in the parental cells. GAPDH was used as the loading control,
data represent one of two independent experiments. d Suppression of
O-GlcNAcylation by siOGT reduced migration and invasion abilities
of parental and highly metastatic CCA cells. e Inhibition of MAN1A1
activity using kifunensine (Kif) enhanced migration and invasion
abilities of CCA cells. f The inhibition effect of siOGT on CCA
migration/invasion could be reversed by Kif treatment. The results are
mean ± SEM of one representation from two independent experiments;
*P < 0.05, **P < 0.01, ***P < 0.001, student’s t test
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Fig. 6 O-GlcNAcylation regulated activations of Akt and Erk and
expression of FOXO3 and MAN1A1. OGT was suppressed in parental
(KKU-213 and KKU-214) and highly metastatic (KKU-213L5 and
KKU-214L5) CCA cells using siOGT. a siOGT treatment inactivated
the phosphorylation of Akt and Erk but not Ikk. b The modulations of
Akt and Erk on FOXO3 expression were revealed using Akt and Erk
inhibitors. CCA cells were treated with various concentrations of Akt
inhibitor, MK-2206 and (c) Erk inhibitor, PD98059, for 24 h. The
expression of pAkt/Akt, pErk/Erk, phospho-FOXO3, FOXO3 and
MAN1A1 were determined using western blotting. d The MK-2206-
treated L5 CCA cells were incubated with 20 µM of cycloheximide
(CHX) for 1, 3, and 6 h. FOXO3 levels at each time point were
determined using western blotting and compared with those of the
untreated control cells. The data are represented as the mean ± SD
from three independent experiments. Inhibition of Akt activation sig-
nificantly reduced (e) migration and (f) invasion abilities of CCA cells
and these effects could be rescued by kifunensine (Kif) treatment. The
results are mean ± SEM of one representative from two independent
experiments. *P < 0.05; **P < 0.01; ***P < 0.001, student’s t test
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FOXO3 positively regulates MAN1A1 expression in
CCA cells
As the level of MAN1A1 expression corresponded well
with FOXO3 expression, we further questioned whether
FOXO3 is a direct modulator of MAN1A1 expression. We
first verified the association of FOXO3 and MAN1A1 by
determination of MAN1A1 expression in siFOXO3 treated
cells. siFOXO3 treatment effectively suppressed FOXO3
and MAN1A1 expression in both parental and highly
metastatic CCA cells (Fig. 7a). Suppression of FOXO3
expression could also significantly suppress expression
levels of MAN1A1 mRNA and protein (P < 0.001, Fig. 7b).
To prove the direct regulation of FOXO3 on MAN1A1
expression, chromatin immunoprecipitation (ChIP) assay
was performed. The primer sequences were designed to
cover the binding region of FOXO3 on MAN1A1 gene as
revealed by EpiTect ChIP qPCR Primers (Fig. 7c). ChIP
assay was conducted in the parental cells, in the presence
and absence of siFOXO3 and MK-2206. The positive
binding of FOXO3 on MAN1A1 gene was detected, as
shown in Fig. 7d and Aupplementary Figure S4. Moreover,
suppression of FOXO3 by siFOXO3 reduced the FOXO3-
binding level, whereas increase of FOXO3 by inhibiting
Akt activity using MK-2206 significantly enhanced the
FOXO3 binding on the endogenous MAN1A1 gene in both
KKU-213 and KKU-214 cell lines. Taken together, this
information suggests for the first time that FOXO3 is a
positive direct regulator of MAN1A1.
Association of O-GlcNAcylation, high-mannose type
N-glycans and MAN1A1 observed in the in vitro
studies were confirmed in patients’ tissues
Upon demonstrating the correlation of OGP, OGT,
MAN1A1 and PSA with cell migration/invasion of CCA
cell lines (Figs 3–5), we next explored whether the same
could be observed in CCA tissues of patients. Immunohis-
tochemistry of OGP, OGT, MAN1A1 and PSA-
histochemistry were performed in five each of non-
metastasis and metastasis CCA cases. As shown in Fig.
8a, b, the expression of OGP, OGT and PSA were elevated
in CCA tissues with metastasis compared to those with non-
metastatic CCA. In contrast, MAN1A1 expression in CCA
tissues with metastasis was lower than that in non-metastatic
CCA. The correlation of OGP, OGT, MAN1A1 and PSA
levels in CCA tissues were determined using Spearman rank
correlation coefficient. As shown in Fig. 8c, OGP had a
positive correlation with expression of OGT and PSA but
had a negative correlation with expression of MAN1A1. In
addition, OGT expression was correlated with OGP levels
while PSA signal was negatively correlated with MAN1A1
expression. These in vivo data confirmed the associations of
Fig. 7 FOXO3 is a positive regulator of MAN1A1. CCA cells were
treated with siFOXO3 for 48 h. The expression of FOXO3 and
MAN1A1 were determined using western blots and real-time PCR.
Compared with scramble (sc) treated cells, suppression of FOXO3
using siFOXO3 decreased expression of FOXO3 and expression levels
of (a) MAN1A1 protein and (b) MAN1A1 mRNA. GAPDH was used
as the loading control. c Schematic illustrations of the locations of
primers and FOXO3-binding region on the MAN1A1 gene used in the
ChIP assays. d Chromatin immunoprecipitation (ChIP) assay was used
to determine the direct binding of FOXO3 on MAN1A1 gene. To
confirm the binding activity of FOXO3 onMAN1A1 gene, ChIP assays
of cells treated with siFOXO3 and MK-2206 for 24 h were performed
and compared to those of control cells. The results are one repre-
sentation from two independent experiments. *P < 0.05, **P < 0.01,
***P < 0.001, student’s t test
5658 C. Phoomak et al.
Fig. 8 CCA tissues with metastasis exhibit high expression of OGP, OGT, and strong PSA binding, with low MAN1A1. a The expression of OGP,
OGT, MAN1A1 and PSA were determined using IHC staining non-metastatic (n= 5) and metastatic (n= 5) CCA tissues. Bars indicate 20 µm. b
Mean expression of OGP, OGT and PSA in metastatic CCA (Met) are significantly higher than that in non-metastatic CCA (Non-met). The
opposite was observed for MAN1A1 expression (*P < 0.05, **P < 0.01; Mann–Whitney test). c The correlations between OGP, OGT, MAN1A1
and PSA levels were shown by Spearman’s rank correlation test (*P < 0.05, **P < 0.01). d Schematic diagram demonstrates the mechanism of O-
GlcNAcylation augmenting metastasis of CCA cells via increasing high mannose type N-glycans. Elevation of O-GlcNAcylation activates Akt and
Erk activities, which further induces phosphorylation of FOXO3. The phosphorylation of FOXO3 by Akt or Erk leads to proteolytic degradation of
FOXO3. The decrease of FOXO3 may cause the reduction of MAN1A1 expression, leading to the elevation of high mannose type N-glycans on
the cell surface. The increase of the high mannose type N-glycan, Man 9, can promote CCA metastasis
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O-GlcNAcylation, high-mannose type N-glycan and
MAN1A1 observed in the in vitro studies.
Discussion
The glycan moieties of glycoproteins and glycolipids on
cell membrane play several important biological roles.
Incomplete synthesis and neo-synthesis of glycans are
commonly found in cancer cells [33]. The regulation of
glycan synthesis, however, is not well understood. The
rationale of this study for the contribution of O-
GlcNAcylation on regulation of N-glycans was initiated
from several observations. First, elevation of O-
GlcNAcylation enhances CCA progression [25, 26]. Sec-
ond, increase of several membranous N-glycans are related
to progression of cancer [34–36]. Finally, O-GlcNAcylation
can regulate many transcriptional factors that modulate the
expression of several proteins including enzymes. These
lines of evidence led us to hypothesize that O-
GlcNAcylation may enhance progression of CCA by
modulation of membranous N-glycans via glycan synthe-
sizing enzymes.
Our study is the first report to demonstrate that O-
GlcNAcylation, an intracellular glycosylation, can modulate
the expression of a cell surface high mannose type N-gly-
can, Hex9HexNAc2, and consequently promote progression
of CCA cells. The molecular link between O-
GlcNAcylation and high mannose type N-glycans via acti-
vation of Akt/Erk, and expression of FOXO3 and MAN1A1
was elucidated. Moreover, the direct regulation of
MAN1A1 expression by FOXO3 was first evidenced in this
study.
Overexpression of OGT in tumor tissues and the asso-
ciation between high O-GlcNAcylation and poor patients’
outcome have been previously reported in CCA [24]. The
in vitro study indicated that the abilities of CCA cells to
migrate and invade could be monitored by modulating O-
GlcNAcylation levels [25]. In addition, higher level of O-
GlcNAc modification in highly metastatic CCA cells than
the parental cells were hitherto observed [26]. In the present
study, we further demonstrate the molecular pathway by
which O-GlcNAcylation modulates progression of CCA. As
the glycan moieties of membrane proteins have a significant
function in adhesion of cell–cell/cell–matrix, cell invasion
and migration, we postulated that O-GlcNAcylation mod-
ulates specific glycan moieties of membrane proteins.
Comparing the glycomic data of membranous N-glycans
between low and highly metastatic CCA cells and between
siOGT treated and scramble control cells suggested a
membranous high mannose type N-glycan, Hex9HexNAc2,
and a biantennary complex type N-glycan, Hex5HexNAc4-
Fuc1NeuAc1, to be associated with metastatic activity and
be mediated by O-GlcNAcylation. Up to our search, this
study is the primary report of the link between O-
GlcNAcylation and the expression of high mannose type
N-glycans.
Normally, mammalian cells scarcely express cell surface
high mannose type N-glycans [37], with the exemption of
stem cells and macrophages [38]. In the current study, these
N-glycans were the highest abundant N-glycans found on
the membranous glycoproteins of CCA cells, indicating
dynamic changes of glycosylation in CCA progression. In
the current study, the significant increase of Hex9HexNAc2
level in the highly metastatic cells was evident from the
glycomic analysis data (Fig. 2c) and PSA-cytofluorescence
signals (Fig. 3e). The involvement of high mannose type N-
glycans and progression of CCA cells was confirmed by the
PSA neutralizing experiment. Masking high mannose type
N-glycans with PSA, a mannose binding lectin, sig-
nificantly reduced the capabilities of CCA cells in migration
and invasion. Notably, the effect of PSA inhibition on
migration and invasion was more obvious in highly meta-
static cells than in the parental cells. This implies that the
magnitude of high mannose type N-glycans is positively
related to the progression of CCA metastasis. The associa-
tion of overexpression of Hex9HexNAc2 with metastasis has
been reported in several types of cancers [34–36]. In addi-
tion, Hex8HexNAc2 glycan was also stated in pancreatic
tumor tissues [39].
O-GlcNAcylation, an intracellular glycosylation, is
involved in key cellular processes, including nutrient sen-
sing, stress response, transcription-translation, signal trans-
duction, and proteolysis by proteasome [21]. To our
knowledge, the connection of O-GlcNAc modification and
the Hex9HexNAc2 expression has never been reported. We
demonstrate that reduction of O-GlcNAcylation with siOGT
significantly reduced cell surface high mannose type N-
glycans. To elucidate how O-GlcNAcylation modulates the
level of Hex9HexNAc2, we first focused on the expression of
MAN1A1, as it is the enzyme that mediates Hex9HexNAc2
processing by removing 3 terminal mannose residues from
Hex9HexNAc2. Suppression of O-GlcNAcylation using
siOGT elevated the expression level of MAN1A1 and con-
sequently reduced the level of Hex9HexNAc2. Conversely,
induction of O-GlcNAcylation using an OGA inhibitor,
PUGNAc, decreased the expression of MAN1A1. These
data support our hypothesis that O-GlcNAcylation can reg-
ulate the level of surface N-glycan via modulating the
expression of glycan synthesizing enzymes, namely
MAN1A1. The significance of O-GlcNAcylation and
MAN1A1 on the progression of CCA metastasis was con-
firmed by the facts that reduction of O-GlcNAcylation
markedly suppressed the migratory and invasion abilities of
both parental and highly metastatic CCA cells (Fig. 5d),
whereas inhibition of MAN1A1 activity by kifunensine
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increased the observed functions (Fig. 5e). We further show
O-GlcNAcylation modulates the progression of CCA
metastasis via MAN1A1 by the finding that reduction of
CCA metastasis by siOGT treatment could be reversed by
inhibiting MAN1A1 activity using kifunensine (Fig. 5f).
We next explored how O-GlcNAcylation regulates
MAN1A1 expression. Our previous study demonstrated
that O-GlcNAcylation could activate Akt signaling and
promote progression of CCA metastasis [25]. This infor-
mation supports our finding that FOXO3, a transcriptional
factor under Akt and Erk activation, is a transcriptional
factor of MAN1A1. Our data led us to propose that FOXO3
is a transcriptional factor that linked O-GlcNAcylation and
Akt and Erk activation to MAN1A1 expression. We
demonstrate the link between FOXO3 and expression of
MAN1A1 by the findings that suppression of FOXO3
expression decreased the expression level of MAN1A1 in
both parental and highly metastatic cells. In addition, the
analysis of EpiTect ChIP qPCR Primers assay suggested
FOXO3 as a possible transcriptional regulator of MAN1A1.
The ChIP assay showed that FOXO3 could bind to the
MAN1A1 gene and that DNA binding of FOXO3 correlated
well with the expression levels of FOXO3, especially in the
FOXO3 suppressed cells or Akt inhibited cells. These data
demonstrated for the first time that FOXO3 is a positive
transcriptional activator of MAN1A1.
The association of O-GlcNAcylation and FOXO3
expression was further shown to be via Akt and Erk acti-
vation. First, suppression of O-GlcNAcylation using siOGT
was able to inhibit the activation of Akt and Erk in both
parental and highly metastatic CCA cells. Second, inhibit-
ing activities of Akt and Erk by their specific inhibitors
reduced the phosphorylation of FOXO3 at Thr-32 and Ser-
294, leading to the increased expression of FOXO3 and
hence MAN1A1.
In agreement with our findings, the association of O-
GlcNAc modification and increased metastatic ability has
been shown in several types of cancers. Activation of PI3K/
Akt and MAPK/Erk pathways have been demonstrated to
be the link between O-GlcNAcylation and metastatic ability
of various cancer cells, including thyroid anaplastic cancer
[40] and breast cancer [41]. It has been shown that elevation
of O-GlcNAcylation by OGA inhibition or overexpression
of OGT could increase Akt phosphorylation at Ser-473 in
thyroid anaplastic cancer cells [40]. In addition, suppression
of O-GlcNAcylation by siOGT decreased O-GlcNAcylation
and phosphorylation of Akt in breast cancer cells [41]. In
primary mouse vascular smooth muscle cells, O-
GlcNAcylation of Akt at Thr-430 and Thr-479 promoted
Akt phosphorylation at Ser-473 and consequently induced
vascular calcification [42].
Furthermore, similar to our finding, earlier reports sug-
gest that activation of Akt and Erk promotes cancer
progression via downregulation of FOXO3 [32] in breast
cancer [43] and uveal melanoma cancer cells [44]. The
mechanism by which Erk activation promotes breast cancer
progression via inhibition of FOXO3 expression has also
been shown to be through MDM2-mediated degradation
[45]. This evidence is consistent with our study that sup-
pression of Akt using the protein synthesis inhibitor
cycloheximide increases the expression level of FOXO3 by
stabilizing the protein. The connection between Akt acti-
vation and MAN1A1 on CCA progression has also been
demonstrated for the first time in this study. Inhibition of
Akt activity markedly inhibited migration and invasion of
highly metastatic CCA cells and these effects could be
rescued by inhibiting MAN1A1 activity using kifunensine
(Fig. 6e, f).
The correlation between MAN1A1 expression and
metastasis has been reported in liver cancer. Lower
expression of MAN1A1 in HCCLM3, MHCC97H, and
MHCC97L, the metastatic hepatoma cells than Hep3B,
the non-metastatic hepatoma cells was reported [46].
Moreover, high expression of MAN1A1 was correlated
with a better outcome of breast cancer patients [47]. The
regulation of MAN1A1 in cancer, however, is still
unclear. It has been shown in melanoma, liver, breast and
cervical cancers that aberrant expression of MAN1A1 is
associated with the status of methylation at promoter
region [48]. Expression level of MAN1A1 was shown to
be modulated via FOXO3 in the present study. MAN1A1
and FOXO3 expression in CCA tissues and their asso-
ciation with clinical pathological features of the patients
should be explored to support the in vitro findings of this
study. Moreover, further investigation is needed on the
roles of the biantennary structure, Hex5HexNAc4Fuc1-
NeuAc1, as well as the truncated complex N-glycans,
Hex5HexNAc3Fuc1 and Hex5HexNAc4Fuc1, in O-
GlcNAc-mediated CCA progression.
Our earlier studies demonstrated the increase of O-
GlcNAcylation in CCA tissues with negative relationship
to survival of CCA patients [24]. In addition, elevation of
O-GlcNAcylation has been shown to increase progres-
siveness of CCA metastasis via activation of Akt and Erk
[25]. In the current study, the molecular link between O-
GlcNAcylation and CCA progression was further
shown to be via increasing of the membranous
high mannose type N-glycan, Hex9HexNAc2. O-
GlcNAcylation activates the PI3K/Akt and MAPK/Erk
signaling pathways which negatively regulates the
expression level of FOXO3 leading to the decreased
expression of MAN1A1 and accumulation of Hex9Hex-
NAc2 (Fig. 8d). These findings reveal new perspectives of
Hex9HexNAc2 as a candidate marker and therapeutic
target for CCA.
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Materials and methods
Antibodies and reagents
Antibodies were obtained from several sources: anti-O-
GlcNAc (RL-2, #MA1-072) from Pierce Biotechnology
(Rockford, IL); anti-MAN1A1 (#M-3694) from Sigma-
Aldrich (St. Louis, MO); anti-pAkt (ser-473, #9271s), anti-
Akt, anti-pFOXO3 (ser-294, #5538s), and anti-pFOXO3 (thr-
32, #9464s) from Cell Signaling (Danvers, MA); anti-Erk (K-
23, #sc-94), anti-pErk (E-4, #sc-7383), anti-pIkk (T23, #sc-
101706), and anti-Ikk (H470, #sc-7607) from Santa Cruz
Biotechnology; anti-FOXO3 (#07–702) and anti-GAPDH
(#MAB-374) from Merck Millipore (Billerica, MA). Akt
inhibitor, MK-2206 dihydrochloride (#sc-364537) was from
Santa Cruz Biotechnology (Santa Cruz, CA) and Erk inhi-
bitor, PD98059 (#9900) was obtained from Cell Signaling
(Danvers, MA). PNGase-F (#P0704) was purchased from
New England Biolabs (Ipswich, MA), Pisum Sativum
Agglutinin (PSA, #L-1050), biotinylated PSA (#B-1055),
biotinylated Concanavalin A (#B-1005) were obtained from
Vector Laboratories (Burlingame, CA). Mannosidase I inhi-
bitor, kifunensine (#K1140), OGA inhibitor, [O-(2-Acet-
amido-2-deoxy-D-glucopyranosylidenamino)-N-phenylcarba-
mate; PUGNAc, #A7229], and cycloheximide (CHX,
#C104450) were purchased from Sigma-Aldrich.
Cell culture and treatments
KKU-213 and KKU-214, the CCA cell lines were provided
from the Japanese Collection of Research Bioresources
(JCRB) Cell Bank, Osaka, Japan. Highly metastatic CCA
sublines; KKU-213L5 and KKU-214L5 were established
from the parental cells, KKU-213 [49] and KKU-214 [50].
All cells were cultured in HAM’s F-12 (Gibco, NY) con-
taining 10% fetal bovine serum (Gibco) and 1% antibiotic-
antimycotic (Gibco), under the standard protocol at 37 °C
and 5% CO2.
OGA inhibitor, PUGNAc, was used to enhance O-
GlcNAcylation level in CCA cells. CCA cells, (8 × 105
cells) in a 6 cm-culture dish were treated with 20 µM
PUGNAc for 24 h prior to further experiments.
Cycloheximide (CHX) a protein synthesis inhibitor, was
used to determine protein stability. Adherent CCA cells
(3 × 105 cells/well) in a 6-well plate were treated with 20 µg/
ml of CHX for the indicated time.
Kifunensine, a mannosidase 1 inhibitor, was used to
inhibit the MAN1A1 activity. After plating 8 × 105 cells per
well in a 6 cm-culture dish for 24 h, 20 µg/ml of kifunensine
was added in each well and the plates were cultured further
for 48 h before subjecting to further experiments.
PSA neutralization test was used to neutralize cell sur-
face mannosylated N-glycans. CCA cells (3 × 105 cells)
were treated with 10 µg/ml of PSA in a complete media for
24 h at 37 oC prior to further experiments.
OGT- and FOXO3- siRNA-treated cells
The level of O-GlcNAcylation was modulated by suppres-
sing OGT expression using specific siRNA as described
previously [51]. The negative control siRNA (scramble
siRNA, QIAGEN, Hilden, Germany) was used as the
control. Similar procedures were performed for siFOXO3
[52].
Preparation of membrane fraction and purification
of membranous N-glycans
The membrane fraction was harvested according to the
standard procedure [53] with minor modification. In brief,
CCA cells were homogenized in 20 mM HEPES-KOH, pH
7.4 containing 0.25M sucrose and 1:100 protease inhibitor,
using probe sonication (25 Amplitude, pulsed on 5 s and off
10 s for 5 times). Cell nuclei were fractionated by cen-
trifugation at 2000 × g, for 10 min. Then, the membrane
fraction was separated by 3 times of ultra-centrifugation at
200,000 × g, 45 min. The final pellet was collected as the
membrane fraction and total N-glycans were released using
1000 U of PNGase-F at 37 °C in a microwave reactor (CEM
Corporation, Matthews, NC) at 20 watts for 10 min. The
released N-glycans were enriched and purified by porous
graphitized carbon solid-phase extraction as described pre-
viously [48]. The unbound fraction was first eluted with
9 ml of pure water and the bound N-glycan fraction was
eluted with 4 ml of 40% ACN and 0.1% TFA in pure water.
Glycomic analysis of membranous N-glycans
Samples were reconsitituted in 30 µl pure water and com-
position of glycans were analyzed by Agilent HPLC-Chip/
Time-of-Flight (Chip/TOF) MS system (Agilent Technol-
ogies, Santa Clara, CA) as previously reported [48]. The
enrichment column was conditioned with 3% ACN and
0.1% formic acid (FA) in water. Sample (5 μl) was injected
at 4.0 μl/min using a 6 °C maintained autosampler. The
mass spectra were analyzed using Agilent MassHunter
Qualitative Analysis software and the extracted compound
chromatograms (ECC) were determined using the Mole-
cular Feature Extractor algorithm. Each compound was
identified using an in-house retrosynthetic library [54]. Area
under the peaks was used for relative quantitation.
Cell aggregation test
To select the appropriated concentration of Pisum Sativum
Agglutinin (PSA), a mannose recognition lectin, cell
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aggregation test was first tested. In a 24-well plate, KKU-
213L5 of 5 × 104 cells per well were incubated in a serum
free Ham’s F-21 media containing 0–100 µg/ml of PSA
for 1 h. The aggregated cells were visualized using a
light microscope. The highest PSA concentration that did
not initiate aggregated cells was selected for further
studies.
PSA-cytofluorescence staining
A solution of 4% paraformaldehyde was used to fix the
cells for 30 min prior to block the non-specific binding
with 0.5% BSA in PBS for 5 min. Cells were then incu-
bated with 0.01 mg/ml of biotinylated PSA (Vector
Laboratories) at 4 °C, overnight and 1 h at room tem-
perature with 1:500 streptavidin-FITC (Invitrogen, UK).
Hoechst 33342 (Molecular probe, Invitrogen) was used to
stain the nuclei and the fluorescent image was visualized
using a ZEISS LSM 800 Confocal Laser Scanning
Microscope (Zeiss, Oberkochen, Germany). The inten-
sities of the fluorescent signals were analyzed using ZEN
2.1 software (Zeiss).
Cell proliferation
Viable cells in a 96-well plate were determined con-
tinuously for 4 days using the MTT proliferation assay
(Moleular probes, Eugene, OR) as previously described
[25]. Proliferation rate (fold change from control) was
determined as OD of treatment/mean OD of control.
Cell migration and invasion
The Boyden chamber assay (8.0 µm pore size, Corning
Incorporated, Corning, NY) was used to determine the
migration and invasion as previously described [25]. For
invasion assay, the upper chambers were pre-coated
overnight with 100 µl of 0.4 mg/ml Matrigel (BD Matri-
gelTM, BD biosciences). At least 5 microscopic fields
of 10 × objective were determined for migrated and
invaded cells. Triplicate tests per experiment were
performed.
Western blot analysis
Cell lysate (30–50 µg) in a NP-40 lysis buffer was loaded
onto a 10% SDS-PAGE and the separated proteins were
electro-transferred onto a PVDF membrane. The immu-
noreactivity and captured signal were determined as men-
tioned previously [25]. Amount of proteins in cell lysates
were measured with Bradford reagent (Bio-rad laboratories,
Hercules, CA) as described by the manufacturer.
RNA extraction and real-time reverse transcriptase
polymerase chain reaction (RT-PCR)
Total RNA extraction and cDNA conversion were per-
formed as described previously [25]. PCR reactions were
performed using 40 ng cDNA, 0.4 µM of the specific for-
ward and reverse primers for MAN1A1 (5′-GTGGA-
CAGTGGGGTCAACAT-3′ and 5′-
GCTGCTAGACTTGCGGATCA-3′) in a total of 10 µl
LightCycle 480® SYBR green I master mix (Roche Diag-
nostic, Mannheim, Germany), using the LightCycle 480®
real-time PCR system (Roche Diagnostic). β-actin expres-
sion was analyzed as an internal control. Gene expression
levels were determined using LightCycle 480® Relative
Quantification software (Roche Diagnostic).
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed using the EZ-ChIPTM chromatin
immunoprecipitation kit (17–371, Upstate, Millipore Cor-
poration) as suggested by the manufacturer. Briefly, after
treating cells with siFOXO3 or Akt inhibitor, the DNA and
proteins were crosslinked using formaldehyde at a final
concentration of 1% (v/v) in culture media. The cells were
sonicated on ice with 5 sets of 15 s pulses on and 10 s pulses
off using Ultrasonic homogenizer (sonic VCX 750, Sonics
& Materials inc., CT), equipped with a 2 mm tip and set to
30% power. The FOXO3-bound DNA was precipitated
with 3 µg/ml of anti-FOXO3 antibody. Rabbit IgG was used
as an isotype control. The chromatin-antibody complexes
were captured with Protein G-Agarose containing Salmon
Sperm DNA. After washing, the DNA–protein cross-links
that bound to Protein G-Agarose were eluted using elution
buffer, and the complexes were reversed at 65 °C overnight
in 0.2M NaCl. Protein was removed from the DNA using
proteinase K at 45 °C for 1 h. The DNA was purified using a
spin column. The FOXO3-binding site on MAN1A1 gene in
the purified DNA and input genomic DNA were analyzed
by real-time PCR, using the primer sequences; primer-1, 5′-
TCCATCAGATTAGTTCAGGCAGA-3′ and primer-2, 5′-
CACTCTTGCCTCTCTAAAGCC-3′ as suggested by Epi-
Tect ChIP qPCR Primers (http://sabiosciences.com/
chipqpcrsearch.php). The results of FOXO3 binding are
normalized against the input DNA.
Immunohistochemistry
The immunohistochemistry (IHC) experiments were per-
formed using formalin-fixed paraffin-embed liver tissues
from histologically proven CCA patients which were
obtained from the specimen bank of Cholangiocarcinoma
Research Institute at Khon Kaen University (Khon Kaen,
O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1 5663
Thailand). Each subject gave informed consent and the
study protocol was certified by the Ethics Committee for
Human Research at Khon Kaen University (HE581369).
Expression levels of OGP, OGT, PSA and MAN1A1 in
10 CCA tissues (non-metastasis (n= 5) and metastasis (n=
5) CCA) were determined using IHC staining according to
the standard protocol [26]. The signals were amplified using
the EnVision-system-HRP (Dako, Glostrup, Denmark). The
immunoreactivity signals were developed using diamino-
benzidine (Sigma-Aldrich). The IHC score was determined
as described previously. Two independent assessors scored
the levels of IHC staining signal blindly without prior
knowledge of clinical parameters.
Statistical analysis
At least two independent experiments and with two biolo-
gical replicates were performed in all experiments. Graph-
Pad Prism® 5.0 software (GraphPad software, Inc., La Jolla,
CA) was used for statistical analysis. P < 0.05 was con-
sidered as statistical significance.
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